FDA DEVICE FACTS
Elecsys Phospho-Tau (217P) Plasma
Roche Diagnostics
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The Elecsys Phospho-Tau (217P) Plasma assay is an in vitro immunoassay for the determination of the phospho-tau (217P) (pTau217) protein in human plasma from individuals aged 55 years and older. The assay is intended for use as an aid in identifying patients with amyloid pathology presenting with signs, symptoms, or complaints of cognitive decline associated with Alzheimer's disease. The Elecsys Phospho-Tau (217P) Plasma assay result must be used in the diagnostic pathway in conjunction with other clinical information. The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。